Stryker Bets $316 Million It Can Invigorate Orthovita's Biologics Biz
This article was originally published in The Gray Sheet
Executive Summary
Stryker hopes its sales force heft can push Orthovita's line of synthetic orthobiologics into a better growth position while filling important competitive gaps.